Download PDF
J Reconstr Microsurg 2024; 40(09): 688-693
DOI: 10.1055/a-2283-4775
Original Article

Outpatient Prescription Opioid Use following Discharge after Deep Inferior Epigastric Perforator Breast Reconstruction with and without an Educational Intervention

Jessica L. Marquez 
1   Department of Surgery, Division of Plastic and Reconstructive Surgery, University of Utah School of Medicine, Salt Lake City, Utah
,
Josh Chow
1   Department of Surgery, Division of Plastic and Reconstructive Surgery, University of Utah School of Medicine, Salt Lake City, Utah
,
Whitney Moss
1   Department of Surgery, Division of Plastic and Reconstructive Surgery, University of Utah School of Medicine, Salt Lake City, Utah
,
Jessica Luo
1   Department of Surgery, Division of Plastic and Reconstructive Surgery, University of Utah School of Medicine, Salt Lake City, Utah
,
Devin Eddington
2   Department of Internal Medicine, Division of Epidemiology, University of Utah School of Medicine, Salt Lake City, Utah
,
Jayant P. Agarwal
1   Department of Surgery, Division of Plastic and Reconstructive Surgery, University of Utah School of Medicine, Salt Lake City, Utah
,
Alvin C. Kwok
1   Department of Surgery, Division of Plastic and Reconstructive Surgery, University of Utah School of Medicine, Salt Lake City, Utah
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

Abstract

Background There is limited evidence for appropriate postoperative opioid prescribing in autologous breast reconstruction. We sought to describe postoperative outpatient prescription opioid use following discharge after deep inferior epigastric perforator (DIEP) breast reconstruction with and without an educational video.

Methods Patients undergoing DIEP reconstruction were given a 28-day postoperative pain and medication logbook from August 2022 to June 2023. Our practice implemented an educational video upon discharge on proper opioid consumption. Descriptive statistics on patient characteristics, intraoperative and postoperative opioid consumption, and outpatient prescription opioid use after discharge were compared between the two cohorts.

Results A total of 53 logbooks were completed with 20 patients in the no video cohort and 33 in the video cohort. On average, the days to cessation of opiates was longer in the no video cohort (8.2 vs. 5.1 days, p = 0.003). The average number of oxycodone 5 mg equivalents consumed following discharge was 13.8 in the no video cohort and 7.8 in the video cohort, which was statistically significant (p = 0.01). Overall, the percentage of opioids prescribed that were consumed in the video cohort was 28.3% versus 67.1% in the no video cohort.

Conclusion For patients discharging home after DIEP reconstruction, we recommend a prescription for 12 oxycodone 5 mg tablets. With the use of an educational video regarding proper opioid consumption, we were able to reduce the total outpatient opioid use to 5 oxycodone 5 mg tablets following hospital discharge.

Keywords

opioid prescribing guidelines - breast reconstruction - postoperative opioids - postoperative pain control

Author Contributions

All authors above appropriately contributed to the development of this manuscript. The conceptualization of the goals/aims of the article were driven by J.P.A. and A.C.K. The formal acquisition of the data was carried out by J.L.M., J.C., W.M., and J.L. Data analysis was conducted by D.E. J.M., J.C., W.M., J.P.A., and A.C.K. were involved in drafting and revising the final version for submission.


Supplementary Material



Publication History

Received: 23 December 2023

Accepted: 20 February 2024

Accepted Manuscript online:
07 March 2024

Article published online:
26 March 2024

© 2024. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Trakimas DR, Perez-Heydrich C, Mandal R. et al. Peri-operative pain and opioid use in opioid-naïve patients following inpatient head and neck surgery. Front Psychiatry 2022; 13: 857083
    CrossrefPubMedGoogle Scholar
  • 2 Upp LA, Waljee JF. The opioid epidemic. Clin Plast Surg 2020; 47 (02) 181-190
    CrossrefPubMedGoogle Scholar
  • 3 Buffington DE, Lozicki A, Alfieri T, Bond TC. Understanding factors that contribute to the disposal of unused opioid medication. J Pain Res 2019; 12: 725-732
    CrossrefPubMedGoogle Scholar
  • 4 Hill MV, McMahon ML, Stucke RS, Barth Jr RJ. Wide variation and excessive dosage of opioid prescriptions for common general surgical procedures. Ann Surg 2017; 265 (04) 709-714
    CrossrefPubMedGoogle Scholar
  • 5 Understanding the epidemic. Centers for Disease Control and Prevention. Accessed October 18, 2023 at: https://www.cdc.gov/drugoverdose/epidemic/index.html
    PubMedGoogle Scholar
  • 6 Howard R, Fry B, Gunaseelan V. et al. Association of opioid prescribing with opioid consumption after surgery in Michigan. JAMA Surg 2019; 154 (01) e184234
    CrossrefPubMedGoogle Scholar
  • 7 Hart AM, Broecker JS, Kao L, Losken A. Opioid use following outpatient breast surgery: are physicians part of the problem?. Plast Reconstr Surg 2018; 142 (03) 611-620
    CrossrefPubMedGoogle Scholar
  • 8 Prescribing recommendations opioid prescribing engagement network. Accessed September 18, 2023 at: https://michagan-open.org/prescribing-recommendations/updated
    PubMedGoogle Scholar
  • 9 Haddock NT, Garza R, Boyle CE, Liu Y, Teotia SS. Defining enhanced recovery pathway with or without liposomal bupivacaine in DIEP flap breast reconstruction. Plast Reconstr Surg 2021; 148 (05) 948-957
    CrossrefPubMedGoogle Scholar
  • 10 Van Boerum MS, Mann SL, Veith JP. et al. Patient-reported opioid use for tissue expander-based breast reconstruction. J Plast Reconstr Aesthet Surg 2021; 74 (11) 2899-2905
    CrossrefPubMedGoogle Scholar
  • 11 Huynh V, Rojas K, Ahrendt G. et al. Reassessing opioid use in breast surgery. J Surg Res 2020; 254: 232-241
    CrossrefPubMedGoogle Scholar
  • 12 Kroll SS, Sharma S, Koutz C. et al; Evans GRD. Postoperative morphine requirements of free TRAM and DIEP flaps. Plast Reconstr Surg 2001; 107 (02) 338-341
    CrossrefPubMedGoogle Scholar
  • 13 Calculating total daily dose of opioids for safer dosage. U.S. Department of Health and Human Services. Accessed August 21, 2023 at: https://www.cdc.gov/drugoverdose/pdf/calculating_total_daily_dose-a.pdf
    PubMedGoogle Scholar
  • 14 Cheah MA, Sarmiento S, Lesko RP. et al. Association of preoperative opioid use and postoperative complications following breast reconstruction. J Plast Reconstr Aesthet Surg 2023; 83: 258-265
    CrossrefPubMedGoogle Scholar
  • 15 Johnson AC, Colakoglu S, Reddy A. et al. Perioperative blocks for decreasing postoperative narcotics in breast reconstruction. Anesth Pain Med 2020; 10 (05) e105686
    CrossrefPubMedGoogle Scholar
  • 16 Persing S, Manahan M, Rosson G. Enhanced recovery after surgery pathways in breast reconstruction. Clin Plast Surg 2020; 47 (02) 221-243
    CrossrefPubMedGoogle Scholar
  • 17 Momeni A, Ramesh NK, Wan D, Nguyen D, Sorice SC. Postoperative analgesia after microsurgical breast reconstruction using liposomal bupivacaine (Exparel). Breast J 2019; 25 (05) 903-907
    CrossrefPubMedGoogle Scholar
  • 18 Offodile II AC, Gu C, Boukovalas S. et al. Enhanced recovery after surgery (ERAS) pathways in breast reconstruction: systematic review and meta-analysis of the literature. Breast Cancer Res Treat 2019; 173 (01) 65-77
    CrossrefPubMedGoogle Scholar
  • 19 Chattopadhyay A, Shah JK, Yesantharao P, Ho VT, Sheckter CC, Nazerali R. Transversus abdominus plane blocks do not reduce rates of postoperative prolonged opioid use following abdominally based autologous breast reconstruction: a nationwide longitudinal analysis. Eur J Plast Surg 2023; 46 (02) 203-213
    CrossrefPubMedGoogle Scholar
  • 20 Lu YH, Jeon J, Mahajan L, Yan Y, Weichman KE, Ricci JA. Postoperative magnesium sulfate repletion decreases narcotic use in abdominal-based free flap breast reconstruction. J Reconstr Microsurg 2024; 40 (07) 559-565
    Article in Thieme ConnectPubMedGoogle Scholar
  • 21 Fearon NJ, Kurtzman J, Benfante N. et al. Reducing opioid prescribing after ambulatory breast reconstruction surgery. J Surg Oncol 2023; 128 (08) 1235-1242
    CrossrefPubMedGoogle Scholar
  • 22 Rodnoi P, Dickey RM, Teotia SS, Haddock NT. Increased opioid consumption following DIEP flap breast reconstruction: effect of depression and anxiety. J Reconstr Microsurg 2022; 38 (09) 742-748
    Article in Thieme ConnectPubMedGoogle Scholar
  • 23 Nelson JA, Polanco TO, Shamsunder MG. et al. Perioperative inpatient opioid consumption following autologous free-flap breast reconstruction patients: an examination of risk and patient-reported outcomes. Ann Surg Oncol 2021; 28 (12) 7823-7833
    CrossrefPubMedGoogle Scholar
  • 24 Egan KG, De Souza M, Muenks E, Nazir N, Korentager R. Predictors of opioid consumption in immediate, implant-based breast reconstruction. Plast Reconstr Surg 2020; 146 (04) 734-741
    CrossrefPubMedGoogle Scholar
  • 25 Egan KG, De Souza M, Muenks E, Nazir N, Korentager R. Opioid consumption following breast surgery decreases with a brief educational intervention: a randomized, controlled trial. Ann Surg Oncol 2020; 27 (09) 3156-3162
    CrossrefPubMedGoogle Scholar
  • 26 Sudduth JD, Moss WD, Clinker C. et al. Scheduled postoperative ketorolac does not decrease opiate use following free flap breast reconstruction. J Reconstr Microsurg 2023; 39 (09) 751-757
    Article in Thieme ConnectPubMedGoogle Scholar
  • 27 Burgess C, Cornelius V, Love S, Graham J, Richards M, Ramirez A. Depression and anxiety in women with early breast cancer: five year observational cohort study. BMJ 2005; 330 (7493) 702
    CrossrefPubMedGoogle Scholar
  • 28 Stark N, Kerr S, Stevens J. Prevalence and predictors of persistent post-surgical opioid use: a prospective observational cohort study. Anaesth Intensive Care 2017; 45 (06) 700-706
    CrossrefPubMedGoogle Scholar
  • 29 McCambridge J, Witton J, Elbourne DR. Systematic review of the Hawthorne effect: new concepts are needed to study research participation effects. J Clin Epidemiol 2014; 67 (03) 267-277
    CrossrefPubMedGoogle Scholar